Previous 10 | Next 10 |
home / stock / mnkkq / mnkkq news
Mallinckrodt Presents Data Evaluating INOmax® (Nitric Oxide) Gas, for Inhalation in a Phase 4 Observational Registry in Neonates with Pulmonary Hypertension at the Pediatric Academic Societies (PAS) 2021 Virtual Meeting - Full results presented for Phase 4 observational reg...
National Association of Manufacturers Selects Mallinckrodt for Two Prestigious Manufacturing Leadership Awards -- Mallinckrodt's Specialty Generics division honored with Collaborative Innovation Leadership Award for its COVID-19 pandemic response -- -- Hobart, New York site ...
Mallinckrodt Gains Support for Its Restructuring Support Agreement from Lenders Holding Approximately $1.3 Billion of Its First Lien Term Loans PR Newswire DUBLIN , March 10, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) (" Mallinckrodt " or the...
Mallinckrodt Announces New England Journal of Medicine Publication of Results from its Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) -- CONFIRM is the largest prospective study (n=300) conducted in patients with HRS-1, a life-threaten...
Mallinckrodt Provides Regulatory Update on StrataGraft® PR Newswire DUBLIN , Feb. 12, 2021 /PRNewswire/ -- Mallinckrodt plc , a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Compan...
The Buxton Helmsley Group Announces Sufficient Shareholder Backing to Call Mallinckrodt Meeting of Shareholders, Begin Realigning Board and Management with Shareholder Interests, Renegotiate Restructuring Plan PR Newswire NEW YORK , Jan. 27, 2021 /PRNewswire/ -- ...
The Buxton Helmsley Group Announces Major Shareholder Backing to Call Mallinckrodt Meeting of Shareholders, Realign Board and Management with Shareholder Interests, Renegotiate Restructuring Plan PR Newswire NEW YORK , Jan. 20, 2021 /PRNewswire/ -- The Mall...
The Buxton Helmsley Group to Call Meeting of Mallinckrodt Shareholders to Realign Board and Management with Shareholder Interests, Renegotiate Restructuring Plan PR Newswire NEW YORK , Jan. 15, 2021 /PRNewswire/ -- The Mallinckrodt board and management ha...
Mallinckrodt Announces Real World Data on Hepatorenal Syndrome (HRS) and Acute Kidney Injury (AKI) in Patients with Liver Disease at The Liver Meeting Digital Experience Advancing American kidney health has been identified as a key public health priority by a 2019 Presidential E...
Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience U.K. retrospective chart review examined potential predictors of treatment response includ...
News, Short Squeeze, Breakout and More Instantly...
MALLINCKRODT TO REPORT EARNINGS RESULTS FOR SECOND QUARTER 2022 AND PROVIDE BUSINESS UPDATE PR Newswire DUBLIN , Aug. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced today that it wil...
Mallinckrodt Emerges from Chapter 11 with Strengthened Balance Sheet and Enhanced Financial Flexibility PR Newswire Appoints Sigurdur Olafsson as President and Chief Executive Officer DUBLIN, Ireland , June 16, 2022 /PRNewswire/ -- Mallinckr...
Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome PR Newswire DUBLIN , June 13, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced the ...